{"id":"W4283779549","doi":"10.1016/j.annonc.2022.04.411","title":"SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Nivolumab; Cohort; Hepatocellular carcinoma; Sorafenib; Population; Oncology; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008407992,0.0003775179,0.0009650155,0.000288266,0.000160587,0.0007441321,0.0003294475,0.0004113394,0.001487556],"category_scores_gemma":[0.0008548553,0.0001537186,0.001520506,0.0003831544,0.0002032517,0.0004741302,0.0002749659,0.0008764865,0.0002961694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007186027,"about_ca_system_score_gemma":0.000538789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002094996,"about_ca_topic_score_gemma":0.004572041,"domain_scores_codex":[0.9997825,0.00007555084,0.00001509923,0.00004294527,0.00003614527,0.00004775063],"domain_scores_gemma":[0.9995692,0.00009812364,0.0001220771,0.0000291775,0.00003593315,0.0001455066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2854179,0.005386185,0.2494407,0.002005348,0.007874705,0.0003620995,0.0001546764,0.005476191,0.006468713,0.0003556967,0.014439,0.4226186],"study_design_scores_gemma":[0.06463055,0.09257354,0.8036416,0.0006341964,0.01230736,0.000923706,0.0002285125,0.005498126,0.002440408,0.0005190631,0.01649347,0.000109553],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772246,0.01690845,0.0001675528,0.0005964485,0.000167239,0.0001072605,0.002267687,0.00005384223,0.002506885],"genre_scores_gemma":[0.9847677,0.00672596,0.0004840952,0.000846388,0.000194206,0.0001006038,0.005225704,0.00001414474,0.001641243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002094996,"threshold_uncertainty_score":0.005213916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06950434111771035,"score_gpt":0.2843961183176281,"score_spread":0.2148917771999178,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}